UNCY
Unicycive Therapeutics, Inc.Company Information
- Company Name
- Unicycive Therapeutics, Inc.
- CIK
- CIK0001766140
- Category
- <br>Emerging growth company
- Ticker: Exchange
- UNCY: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- UNCY
SEC filing data through
Insider Sentiment
- Last purchase
- 2022-05-16
- Last sale
- —
- Shares purchased (TTM)
- 15,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 11,634,741
- Shares outstanding
- 26,917,266
- Ownership
- 43.22%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- -4.27%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A2 Preferred Stock | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Series B1 Preferred Stock | - | - | - | - | - | 0 | 0 | 0 | -0 | 0 | 0 | - | ||||||
| Preferred Stock | - | - | - | - | - | - | 0 | 0 | 0 | - | 0 | - | ||||||
| Series B2 Preferred Stock | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 44 | 37 | 29 | 43 | 22 | 20 | 26 | 32 | 42 | 49 | - | 14 | ||||||
| Prepaid Expense And Other Assets Current | 10 | 9 | 8 | 8 | 7 | 8 | 5 | 5 | 2 | 3 | 4 | 4 | ||||||
| Cash | - | - | - | - | - | - | 26 | - | - | - | 10 | - | ||||||
| Marketable Securities Current | 17 | 17 | 12 | - | - | - | - | - | - | - | - | - | ||||||
| Assets Current | 71 | 64 | 49 | 50 | 30 | 27 | 31 | 38 | 44 | 52 | 13 | 19 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 72 | 64 | 49 | 51 | 30 | 28 | 32 | 39 | 45 | 52 | 14 | 19 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 2 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 2 | 3 | 2 | 3 | 2 | 4 | 4 | 3 | 3 | 4 | 3 | 3 | ||||||
| Loans Payable Current | - | - | - | - | - | - | - | - | - | 0 | - | - | ||||||
| Dividends Payable Current | - | - | - | - | - | - | - | - | 0 | - | - | - | ||||||
| Warrants And Rights Outstanding | 14 | 22 | 17 | 9 | 10 | 11 | 19 | 6 | 8 | 25 | 13 | 12 | ||||||
| Operating Lease Liability Current | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 19 | 26 | 19 | 13 | 14 | 17 | 24 | 10 | 13 | 30 | 18 | 15 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Liabilities | 19 | 27 | 19 | 13 | 14 | 17 | 24 | 11 | 13 | 31 | 18 | 16 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | -0 | - | - | - | - | - | - | - | - | - | ||||||
| Additional Paid In Capital | 196 | 178 | 158 | 151 | 123 | 112 | 109 | 107 | 61 | 61 | 61 | 60 | ||||||
| Retained Earnings Accumulated Deficit | -142 | -141 | -128 | -113 | -107 | -128 | -101 | -80 | -76 | -86 | -65 | -57 | ||||||
| Stockholders Equity | 53 | 38 | 30 | 37 | 16 | 11 | 7 | -28 | -15 | -24 | -4 | 3 | ||||||
| Liabilities And Stockholders Equity | 72 | 64 | 49 | 51 | 30 | 28 | 32 | 39 | 45 | 52 | 14 | 19 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | - | - | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 28 | 25 | 22 | 21 | 14 | 12 | 11 | 10 | 4 | 4 | 3 | 3 | ||||||
| Shares Outstanding | 28 | 25 | 22 | 21 | 14 | 12 | 11 | 10 | 4 | 4 | 3 | 3 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialUnicycive Therapeutics, Inc. (UNCY) — SEC Financial Statements & Analysis
Unicycive Therapeutics, Inc. (UNCY) is a pharmaceutical preparations company, incorporated in DE. Unicycive Therapeutics, Inc. trades on Nasdaq as: UNCY. Unicycive Therapeutics, Inc. (UNCY)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Unicycive Therapeutics, Inc. carries a market cap of $126.24M, a P/E ratio of -3.59x, a P/B ratio of 2.37x, a P/S ratio of 31.56x, an enterprise value of $82.06M, and an EV/EBITDA multiple of -2.48x. On profitability, it posts an operating margin of -3077.63%, a net margin of -4525.04%, a Return on Equity (ROE) of -100.90%, a Return on Assets (ROA) of -68.93%, and a Return on Invested Capital (ROIC) of -2079.82%. Per share, it reports EPS of $-1.31, diluted EPS of $-1.31, free cash flow per share of $-1.03, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 8.38% year-over-year, and EPS growth of -50.47% year-over-year. On the balance sheet, it maintains a current ratio of 3.81x, a quick ratio of 3.28x, working capital of $52.62M, a debt-to-equity ratio of 0.35x, a debt ratio of 0.26, an interest coverage ratio of -770.74x, free cash flow of $-27.85M (TTM), and net debt of $-44.19M. Figures sourced from SEC EDGAR.
- Market Cap
- $126.24M
- P/E TTM
- -3.59x
- EPS TTM
- $-1.31
- P/B TTM
- 2.37x
- ROE TTM
- -100.90%
- ROA TTM
- -68.93%
- Debt To Equity
- 0.35x
- Free Cash Flow TTM
- $-27.85M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Unicycive Therapeutics, Inc. in?
Unicycive Therapeutics, Inc. (UNCY) operates in the Pharmaceutical Preparations industry.
What exchange does UNCY trade on?
Unicycive Therapeutics, Inc. (UNCY) trades on the Nasdaq.
Where is Unicycive Therapeutics, Inc. incorporated?
Unicycive Therapeutics, Inc. is incorporated in DE.
When was Unicycive Therapeutics, Inc. (UNCY)'s most recent SEC filing?
Unicycive Therapeutics, Inc. (UNCY)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is UNCY's market cap?
Unicycive Therapeutics, Inc. (UNCY) has a market capitalization of $126.24M as of 2026-06-30.
What is UNCY's EPS (earnings per share)?
Unicycive Therapeutics, Inc. (UNCY)'s trailing twelve month EPS is $-1.31 as of 2026-06-30.
What is UNCY's ROE (return on equity)?
Unicycive Therapeutics, Inc. (UNCY)'s trailing twelve month Return on Equity (ROE) is -100.90% as of 2026-06-30.
What is UNCY's ROA (return on assets)?
Unicycive Therapeutics, Inc. (UNCY)'s trailing twelve month Return on Assets (ROA) is -68.93% as of 2026-06-30.
What is UNCY's ROIC (return on invested capital)?
Unicycive Therapeutics, Inc. (UNCY)'s trailing twelve month Return on Invested Capital (ROIC) is -2079.82% as of 2026-06-30.
What is UNCY's EV/EBITDA?
Unicycive Therapeutics, Inc. (UNCY)'s trailing twelve month EV/EBITDA is -2.48x as of 2026-06-30.